Puma biotechnology director Cesano sells shares worth $566,994

Alessandra Cesano, a director at Puma Biotechnology, Inc., traded 62,150 shares of the company's stock on September 14, 2026, according to a report. The sale, executed under a pre-approved plan, earned Cesano roughly $566,994. The shares were traded at prices between $9.03 and $9.2. Later in the same day, Cesano used stock options she had been granted to buy 50,000 additional shares, spending $146,500.

This brought her total holdings to 56,700 shares of common stock and 50,000 stock options. Despite this insider sale, Puma Biotechnology's stock is currently trading at $9.39, close to its 52-week high of $9.73, after a strong 116% increase over the last year. InvestmentPro analysts suggest the stock is undervalued, with a Fair Value of $11.63, indicating possible future appreciation.

The company trades at a P/E ratio of 18.4 and a market capitalization of $485 million. InvestingPro provides 11 additional expert tips for those interested in PBYI. Recently, Puma Biotechnology reported strong second-quarter 2026 results, beating expectations with $56.5 million in revenue and GAAP earnings of $0.16 per diluted share.

This marked a return to profitability after a loss in the prior quarter. Revenue grew by 9% year-over-year, driven primarily by increased sales of NERLYNX.